The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Recursion Pharmaceuticals Inc shares valued at $961,400 were sold by Borgeson Blake on Dec 02 ’25. At $4.37 per share, Borgeson Blake sold 220,000 shares. The insider’s holdings dropped to 6,869,863 shares worth approximately $33.8 million following the completion of this transaction.
Also, Gibson Christopher purchased 40,000 shares, netting a total of over 185,200 in proceeds.
Before that, Borgeson Blake had added 220,000 shares to its account. In a trade valued at $961,400, the Director bought Recursion Pharmaceuticals Inc shares for $4.37 each.
Analysts at Morgan Stanley started covering the stock with ‘”an Equal-weight”‘ outlook in a report released in late May. As of March 16, 2023, Needham has initiated its “Buy” rating for RXRX. Earlier on September 16, 2022, KeyBanc Capital Markets initiated its rating. Their recommendation was “an Overweight” for RXRX stock.
Analyzing RXRX Stock Performance
On last trading session, Recursion Pharmaceuticals Inc [NASDAQ: RXRX] rose 5.58% to $4.92. The stock’s lowest price that day was $4.58, but it reached a high of $4.94 in the same session. During the last five days, there has been a surge of approximately 11.56%. Over the course of the year, Recursion Pharmaceuticals Inc shares have dropped approximately -35.09%. Shares of the company reached a 52-week high of $12.36 on 02/18/25 and a 52-week low of $3.79 on 04/09/25.
Support And Resistance Levels for Recursion Pharmaceuticals Inc (RXRX)
According to the 24-hour chart, there is a support level at 4.69, which, if violated, would cause prices to drop to 4.45. In the upper region, resistance lies at 5.05. The next price resistance is at 5.17. RSI (Relative Strength Index) is 54.71 on the 14-day chart, showing neutral technical sentiment.
Is Recursion Pharmaceuticals Inc subject to short interest?
Stocks of Recursion Pharmaceuticals Inc saw a sharp rise in short interest on 2025-11-14 jumping by 19.31 million shares to 145.66 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 126.35 million shares. A jump of 13.26% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.42 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.42.
Which companies own the most shares of Recursion Pharmaceuticals Inc (RXRX)?
In terms of Recursion Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 8.5 in the next 12 months, up nearly 82.4% from the previous closing price of $4.66. Analysts anticipate Recursion Pharmaceuticals Inc stock to reach 12 by 2025, with the lowest price target being 6. In spite of this, 3 analysts ranked Recursion Pharmaceuticals Inc stock as Buy at the end of 2025. On April 18, 2022, BofA Securities assigned a price target of “a Neutral” to the stock and downgraded coverage with a $10.
